<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870179</url>
  </required_header>
  <id_info>
    <org_study_id>PR 2016-191</org_study_id>
    <nct_id>NCT02870179</nct_id>
  </id_info>
  <brief_title>Oxitone Sp02 Hypoxia Test Versus Reference Pulse Oximetry</brief_title>
  <official_title>Oxitone Sp02 Hypoxia Test Versus Reference Pulse Oximetry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxitone Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinimark, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxitone Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to conduct a SpO2 hypoxia evaluation of the Oxitone Medical
      Oxitone 1000 pulse oximeter. The Oxitone 1000 pulse oximeter will be evaluated during
      non-motion conditions over the range of 70-100% SpO2 in comparison to a Reference Pulse
      Oximeter.

      The study is observational in nature which quantifies device performance and accuracy in
      compassion to a Reference Pulse Oximeter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to conduct a SpO2 hypoxia evaluation of the Oxitone Medical
      Oxitone 1000 pulse oximeter. The Oxitone 1000 pulse oximeter will be evaluated during
      non-motion conditions over the range of 70-100% SpO2 in comparison to a Reference Pulse
      Oximeter. The end goal is to show the SpO2 accuracy performance of the Oxitone 1000 and if
      needed, use the data to make improvements prior to an arterial blood hypoxia study.

      A Clinimark 3900 Reference Pulse Oximeter or Nellcor N-600x will be used for the SpO2
      calibration. There are no risks or adverse device effects to be assessed. There are no
      contraindications for use in the proposed study / study population

      The Control Pulse Oximeter, GE Healthcare (Datex-Ohmeda) 3900, an FDA cleared device, is
      used to monitor the oxygen saturation levels real time throughout the study for subject
      safety and to target stable plateaus. This device is used to assess the stability of the
      data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collect SpO2 data for accuracy statistical analysis by 12 subjects</measure>
    <time_frame>2 months</time_frame>
    <description>Data is collected in a digital form for 4-6 SpO2 stable plateaus in a specified range from 100% to 70%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy data analysis</measure>
    <time_frame>2 months</time_frame>
    <description>Bland-Altman graphical plots. An Accuracy Root Mean Square (ARMS) calculation is used as a means to define the SpO2 accuracy. Data analysis will follow ISO80601-2-61, Annex EE and the FDA Guidance Document for Pulse Oximeters (Martch 4, 2013).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Error plots</measure>
    <time_frame>2 months</time_frame>
    <description>SpO2 versus (SpO2-Ref SpO2) will be generated with linear regression fit, mean, and upper 95% and lower 95% limits of agreement.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hypoxia</condition>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <description>Smoker or non-smoker</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulse Oximeter</intervention_name>
    <description>Measurement of physiological parameters</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <other_name>Blood Pressure</other_name>
    <other_name>Respiratory Rate</other_name>
    <other_name>Respiratory Gassess</other_name>
    <other_name>Temperature</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of the Denver metropolitan area
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals between the age of 18-50

        Exclusion Criteria:

          -  Clotting disorders, diabetes, currently taking psychotropic medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon Eisen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxitone Medical Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dena M Raley, BSBE</last_name>
    <phone>303-249-6010</phone>
    <email>DMRaley@Clinimark.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul B Batchelder, RRT</last_name>
    <phone>303-717-4820</phone>
    <email>PBatchelder@Clinimark.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinimark Laboratories</name>
      <address>
        <city>Louisville</city>
        <state>Colorado</state>
        <zip>80027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul B Batchelder, RRT</last_name>
      <phone>303-717-4820</phone>
      <email>PBatchelder@clinimark.com</email>
    </contact>
    <investigator>
      <last_name>Paul B Batchelder, RRT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 12, 2016</lastchanged_date>
  <firstreceived_date>August 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oxitone Medical Ltd.</investigator_affiliation>
    <investigator_full_name>Leon Eisen, PhD</investigator_full_name>
    <investigator_title>Leon Eisen, CEO</investigator_title>
  </responsible_party>
  <keyword>Pulse Oximetry</keyword>
  <keyword>Temperature</keyword>
  <keyword>Respiratory Rate</keyword>
  <keyword>Respiratory Gases</keyword>
  <keyword>This study determines the measurement accuracy of the physiological parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
